Compare RAIL & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAIL | PROF |
|---|---|---|
| Founded | 1901 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Railroads | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.1M | 248.8M |
| IPO Year | 2005 | 2017 |
| Metric | RAIL | PROF |
|---|---|---|
| Price | $6.84 | $5.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 167.8K | 120.7K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.94 | 25.89 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $500,991,000.00 | $16,098,000.00 |
| Revenue This Year | $6.54 | $92.40 |
| Revenue Next Year | $30.90 | $64.10 |
| P/E Ratio | $21.28 | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $6.57 | $3.92 |
| 52 Week High | $14.90 | $8.95 |
| Indicator | RAIL | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 40.95 | 27.52 |
| Support Level | $6.57 | $4.97 |
| Resistance Level | $8.70 | $6.06 |
| Average True Range (ATR) | 0.26 | 0.35 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 28.58 | 16.23 |
FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.